Avacta Group plc! Innovation for global health! Interim Results! 25th April 2012!

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Avacta Group plc! Innovation for global health! Interim Results! 25th April 2012!"

Transcription

1 Avacta Group plc Innovation for global health Interim Results 25th April 2012

2 Important Notice This presentation does not constitute a recommendation regarding the shares of Avacta Group plc (the Company ) nor a representation that any dealing in those shares is appropriate. The Company accepts no duty of care whatsoever to the reader of this presentation in respect of its contents and the Company is not acting in any fiduciary capacity. No offer or invitation or solicitation of any offer to acquire securities of the Company is being made now nor does this presentation constitute or form part of any invitation or inducement to engage in investment activity under section 21 of the Financial Services and Markets Act No reliance may be placed for any purpose whatsoever on the information contained in this presentation or any assumptions made as to its completeness and no warranty or representation is given by or on behalf of the Company nor its directors, employees, agents, and advisors as to the accuracy or completeness of the information or opinions contained in this presentation and no liability is accepted by any of them for any such information or opinions, provided that nothing in this paragraph shall exclude liability for any representation or warranty made fraudulently. The information and opinions contained in this presentation are provided as at the date hereof. The contents of this presentation are confidential and must not be copied, published, reproduced, distributed or passed in whole or in part to others at any time by recipients. This presentation is being provided to recipients on the basis that they keep confidential any information contained herein or otherwise made available, whether oral or in writing, in connection with the Company. In particular, this presentation should not be distributed, published or reproduced in whole or in part or disclosed by recipients to any other person or entity and, in particular, should not be distributed to United States residents, corporations, or other entities, US persons (as defined in Regulation S promulgated under the United States Securities Act of 1933 (as amended)), persons with addresses in the United States of America (or any of its territories or possessions), Canada, Japan, the Republic of Ireland, the Republic of South Africa or Australia, or to any corporation, partnership or other entity created or organised under the laws thereof, or in any other country outside the United Kingdom where such distribution may lead to a breach of any law or regulatory requirement. Notwithstanding the foregoing, the Company can distribute this document to US Persons (as defined above), persons with addresses in the United Stats of America (or its territories or possessions), United States residents, corporations or other entities if the Company is satisfied that an applicable exemption applies. Distribution of this document in the United States of America in the absence of such an applicable exemption may constitute a violation of United States of America securities law. By agreeing to receive this presentation you agree to be bound by the foregoing restrictions. 2

3 Avacta Overview

4 Innovation for Global Health Tools to help drive down the cost of healthcare Our purpose is to drive down the cost of healthcare around the world by providing better tools to help reduce the cost of drug development and to improve diagnostics. High cost of drugs Pressure from insurers Wrong/ delayed treatment Pressure from patients High cost of healthcare Pressure from governments Slow/ inadequate diagnostics Pressure from regulators Long hospital stays 4

5 Market Strategy Large healthcare markets with high growth potential Our market strategy is to build from largely unregulated markets towards the more highly regulated, but higher value, human diagnostics market. Biopharmaceuticals $202bn market by 2013 Fastest growing pharma sector 20% CAGR >1/3rd of all drugs in development 2,500-7,000 biotech ventures worldwide Life Science Instruments and Reagents $10bn market Protein Microarrays $2bn market Veterinary Health Veterinary diagnostics $2-3bn 25,000 vets in EU; 25,000 vets in US Veterinary Point of Care Immunodiagnostics $1bn market Human Health In-vitro diagnostics market $50bn POC diagnostics $19bn in 2011 Companion Diagnostics $300m and huge growth potential driven by personalised medicine 5

6 Product Strategy End user driven product development from discovery to diagnostics Our product strategy is to combine high technology, consumables and reagents to provide better tools that help reduce the costs and risk of drug development and that provide improved diagnostics. Our Products and Pipeline Optim 1000 New QC Product Development AX.1 (Vet) Protein Microarrays Discovery/R&D Tools Laboratory Diagnostics/ Manufacturing QC Tools Companion Diagnostics Diagnostics How We Fit With Our Customers Processes Drug/Biomarker Discovery Preclinical R&D Phase I/II Phase III Manufacturing & Commercialisation Patient Care 6

7 Current Products Better tools for drug development and diagnostics Optim 1000 Protein Analysis System Optim 1000 is the only product that allows detailed stability analysis of biological drugs cost effectively and quickly, very early in development to weed out potential failures and reduce wasted development costs Installed base of 27 (at Jan ) including many top ten pharma sites AX-1 Rapid Blood Testing System AX-1 allows laboratory standard blood tests, not cut down versions, to be simply carried out in-clinic Rapid, easy to use and very sensitive Multiple analytes in one instrument Opportunity to create a large menu of different blood tests for veterinary and human healthcare Shipping later in FY k per unit Average 10 per test 92.5k per unit 240 per test 7

8 Acquisition of Affinity Reagents Platform Connecting Avacta s markets from discovery to diagnostics Antibodies are the major class of affinity reagents with multiple markets worth over $300bn Avacta acquired the Affimer affinity reagents platform in January 2012 Affimers are not based on antibodies but on a small protein called Stefin A which has two loops that can be modified to create large numbers of antibody-like reagents each capable of binding a different target Affimers have clear cost and performance advantages compared with antibodies Protein microarrays produced using Affimers could provide best in class drug and biomarker discovery tools which can follow drugs through development and become companion diagnostics in direct response to new FDA guidelines 8

9 Management Team Extensive commercial experience and world class technical expertise Group Chief Executive and Founder Dr Alastair Smith World class scientific and technical expertise with a highly commercial approach Formerly Professor and Director of the Institute of Molecular Biophysics, Leeds University Chief Finance Officer Tim Sykes Extensive commercial and corporate transactions track record in high growth SMEs Previously Associate Director in KPMG Transactions Services Group Chief Executive Avacta Analytical Chris Dryden Technical and commercial management of entrepreneurial hightech businesses Expertise in market entry and growth strategies for high value hardware and software products Chief Executive Avacta Animal Health Ged Holmes Extensive sales, marketing and management experience across a range of multi-national corporates and SME businesses focused on technology and software 9

10 Outlook A solid base with huge growth potential in diagnostics Good growth towards breakeven of core businesses with AX-1 to come Fully funded to execute an accelerated growth programme with two huge potential opportunities : Huge Growth Potential in Diagnostics 1. Significant growth potential of AX-1 as installed base and test menu is grown Example return with an AX-1 installed base of 1000 units each doing 20 tests per week at 10 per test : ~ 10m recurring consumable revenues at 70% GP 2. Large opportunity for our proprietary reagents (Affimers) to dominate the protein microarrays market and provide unique discovery to diagnostics platform in direct response to new FDA personalised medicine guidelines 10

11 Business Update

12 Avacta Group plc Interim Results for the Period Ended 31 st January 2012 Solid growth in underlying revenues and significant reduction in operating losses H1 FY12 m H1 FY11 m FY11 Revenues Gross profit Gross margin 55.7% 50.1% 48.2% Overhead (1.33) (1.04) (2.10) Underlying operating loss (0.39) (0.54) (0.92) Amortisation and SBPs (0.13) (0.06) (0.20) Reported operating loss (0.52) (0.60) (1.12) Retained loss (0.35) (0.36) (0.59) EPS (0.02p) (0.03p) (0.04p) 12

13 Avacta Group plc Balance Sheet and Cash Flow at 31 st January 2012 Cash flow extracts 31/1/12 m 31/1/11 m 31/7/11 m Operating cash flow (0.26) (0.36) (0.59) Investing activities (0.57) (0.44) (1.02) Financing activities Net cash flow Balance sheet extracts 31/1/12 m 31/1/11 m 31/7/11 m Intangible assets Property, plant and equipment Cash Other net current assets Non-cash liabilities (0.26) (0.27) (0.26) Net assets

14 Commercial Highlights Solid growth in Optim sales and pipeline; AX-1 expected to ship this FY Analytical Business Unit H H Optim Despatch 13 8 Optim Installed Base Optim Revenue 0.70m 0.19m Consumable Revenue 0.11m 0.02m 12 8 Optim 1000 Installed Base (27) 7 Analytical CRO services offering expansion into US through partnership with Pall Life Sciences Stand alone Optim software package and seat licenses launched First two acute phase protein tests for dog and cat completed AX-1 in final stages of test validation and manufacturing scale up 14

15 Growth Drivers Key performance indicators for FY2012/13 Optim Analytical Business Unit Sales target 25 (FY12) - installed base 39 Currently 16 units despatched this FY Distribution in India/Brazil by end FY12 India about to sign Additional applications : 4 by end FY12 On schedule Stand alone software : launched Jan 12 Achieved Services Additional business development resource (2 FTE) added in Europe In place; sales pipeline seeing effect First revenue from US services collaboration with Pall Life Sciences First contract won AX-1 Animal Health Business Unit Shipping first units during FY12 - Delayed but still on track for shipping in FY12 Rapid growth of test menu - Recruitment of larger team underway - Menu of tests for development identified and validated Other Test Kits and Services Distribution deal in place for first two tests before end First supply agreement with IDEXX signed; second in pipeline Two more tests in development Multiple companion animal and livestock applications under review 15

16 Other Newsflow in the Period Appointment of Ged Holmes as CEO of Avacta Animal Health, September 2011 Expansion of Optim distribution into SE Asia through Pall Life Sciences, October 2011 Appointment of Panmure Gordon, October M placing and acquisition of affinity reagents platform, January 2011 Post Period End Appointment of Michael Albin as commercial advisor, March 2012 Appointment of Riccardo Pigliucci as strategic business development advisor, March 2012 Supply agreement with IDEXX, April 2012 Michael Albin 12 years with Applied Biosystems rising to VP, Science and Technology Pivotal in the development of the technology that sequenced the human genome Now life sciences consultant to businesses and investors Riccardo Pigliucci 23 years with Applera Corp (formerly Perkin Elmer Corp) rising to President and Chief Operating Officer Also CEO Life Science International Plc and Discovery Partners Inc Now providing strategic consultancy to life sciences and instrumentation companies globally 16

17 Accelerating Growth Through Innovation and Investment

18 Investment to Accelerate Growth End user driven product development from discovery to diagnostics Fully funded to invest in a three year programme : AX-1 veterinary test menu expansion New quality control technology for biopharma manufacturing New protein microarray drug and biomarker discovery tools which can be leveraged to provide entry into human companion diagnostics. New QC Product Development AX-1 test menu expansion Protein Microarrays Companion Diagnostics Discovery/R&D Tools Laboratory Diagnostics/ Manufacturing QC Tools Diagnostics 18

19 The Case for Companion Diagnostics Different people respond differently to a given drug treatment In many human diseases drugs only work for 50% of patients or fewer This results in costly drug development failures at the clinical trials stage and drugs that could help some patients never reaching the market Millions of patients are currently prescribed ineffective and expensive treatments Tests that identify which patients will respond to a given drug (companion diagnostics) maximise the success of clinical trials and target the right drug to the right patients helping drive down the cost of global healthcare Figure2.OneSizeDoesNotFitAll PERCENTAGEOFTHEPATIENTPOPULATIONFORWHICH APARTICULARDRUGISINEFFECTIVE,ONAVERAGE ANTI&DEPRESSANTS(SSRIs) 38% ASTHMADRUGS 40% DIABETESDRUGS 43% ARTHRITISDRUGS 50% ALZHEIMER SDRUGS 70% CANCERDRUGS 75% Sourceofdata:BrianB.Spear,MargoHeath&Chiozzi,JefferyHuff, ClinicalTrendsin MolecularMedicine, Volume7,Issue5,1May2001,Pages201&

20 The Drug Developers Perspective New drugs will require development of a companion diagnostic The FDA and other regulatory bodies are going to require new drugs to have companion diagnostics to identify those patients who will benefit from the treatment The guidance is that the same diagnostic platform should be used to develop the drug and to provide the companion diagnostic from discovery to diagnostics Affimer based protein microarrays provide a combined discovery/diagnostic platform to satisfy regulatory guidelines In Vitro Companion Diagnostic Devices FDA DRAFT GUIDANCE July 14, 2011 Ideally, a therapeutic product and its corresponding IVD companion diagnostic device would be developed contemporaneously, with the clinical performance and clinical significance of the IVD companion diagnostics device established using data from the clinical development program of the corresponding therapeutic product. 20

21 Protein Microarrays A discovery/diagnostic tool limited only by reagent availability Two dimensional arrays of capture (affinity) reagents used to characterise the protein content of complex samples e.g. blood $2bn protein microarray market currently limited only by availability of antibody affinity reagents Antibody arrays are typically a few hundred pixels in size because there is a limited range of antibodies available Avacta s proprietary affinity reagents Affimers could replace antibodies as the affinity reagent of choice Avacta already has a 17,000 Affimer array and is working towards a 100,000 array which should be the best in class affinity microarray Y"Y" Y" Y" Y"Y" Y" Y" Y"Y" Y" Y" Y"Y" Y" Y"Y" Y" Y" Y"Y" Y" Y" = affinity reagent molecule 21

22 Affimers Unlocking the potential of protein microarrays with Affimer reagents Antibodies are the major class of affinity reagents with multiple markets worth over $300bn Avacta s Affimer reagents are not based on antibodies but on a small protein called Stefin A which has two loops that can be modified to create large numbers of reagents each capable of binding a different target Competitive Advantages The AffimerStructure Faster Better Cheaper Months to deliver new reagents not years Much wider range of affinity properties possible Much more robust especially on surfaces like arrays Much cheaper to manufacture using simple processes. than antibodies 22

23 The Protein Microarray Opportunity A non-capex driven high margin revenue stream Global Biochip (DNA Microarrays, LabonChip, Protein Microarrays, Tissue & Cell Arrays) Market: Trends & Forecast ( ) The global protein microarray market was valued $595 million in 2010 and is expected to grow at a CAGR of 19.9% during Diagnostics represents the highest potential application market growing at a CAGR of 24.8% Affimer arrays under development targeting validation with pharma partners Business Model There is already an established installed base of microarray readers for DNA and protein arrays No requirement to develop hardware or grow installed base Non-capex driven high margin recurring revenue stream through sales of arrays and reagents Route to Market Direct sales of arrays to drug and diagnostic developers Commercial partnership with established diagnostic developer Licensing of reagents for specific diagnostic applications 23

24 Summary A solid base and fully funded to accelerate growth Proprietary technology products with recurring consumables and reagents revenue First phase of product development completed Good growth in revenue and contribution from AX-1 yet to come Two operating businesses entirely focused on commercialisation and making steady progress to profitability Fully funded accelerated growth programme to exploit existing Avacta IPR Huge potential growth in diagnostics driven by expanding AX-1 menu and developing companion diagnostics based on proprietary protein microarrays 24

The Stock Market Show. Parsortix non-invasive cancer diagnostics. Andrew Newland 13 September 2014

The Stock Market Show. Parsortix non-invasive cancer diagnostics. Andrew Newland 13 September 2014 The Stock Market Show Parsortix non-invasive cancer diagnostics Andrew Newland 13 September 2014 Legal disclaimer The information and opinions contained in this presentation are provided as at the date

More information

Investor presentation

Investor presentation Public Company Limited Investor presentation February 2013 Page 0 Disclaimer This presentation is the sole responsibility of the directors of Urals Energy PCL (the Company ). Allenby Capital Limited (

More information

Avacta Group plc. Innovation for global health. Interims results for the period ended 31 st January 2015. Avacta Group plc

Avacta Group plc. Innovation for global health. Interims results for the period ended 31 st January 2015. Avacta Group plc Avacta Group plc Innovation for global health Interims results for the period ended 31 st January 2015 Avacta Group plc Overview Avacta (AIM: AVCT) is a global provider of proprietary diagnostic tools,

More information

Life Science - a sustainable platform for profitable growth

Life Science - a sustainable platform for profitable growth Life Science - a sustainable platform for profitable growth 2012 Life Science Information Day Bernd Reckmann Member of the Executive Board and Head of Chemicals Molsheim, France - December 5, 2012 Agenda

More information

Presented at: Jefferies 2015 Global Healthcare Conference

Presented at: Jefferies 2015 Global Healthcare Conference Presented at: Jefferies 2015 Global Healthcare Conference Agenda 1 Overview & Service Platforms 2 Adaptability, Scalability & Expansion Plans 3 Best Practices 4 Blue Chip Customer Base 5 Roadmap of Evolution

More information

VOLEX INTERIM RESULTS TO OCTOBER 5 2014. Christoph Eisenhardt, CEO Nick Parker, CFO November 2014

VOLEX INTERIM RESULTS TO OCTOBER 5 2014. Christoph Eisenhardt, CEO Nick Parker, CFO November 2014 VOLEX INTERIM RESULTS TO OCTOBER 5 2014 Christoph Eisenhardt, CEO Nick Parker, CFO November 2014 Disclaimer This Presentation has been prepared by Volex PLC (the Company ) in connection with the publication

More information

Avacta Group plc. Unaudited Preliminary Results for the year to 31 July 2008

Avacta Group plc. Unaudited Preliminary Results for the year to 31 July 2008 Avacta Group plc Unaudited Preliminary Results for the year to 31 July 2008 Avacta Group plc ( Avacta, the Group or the Company ) which develops detection and analysis technology and services aimed at

More information

April 2016. Bruno Jactel, CEO Erica Boisvert, CFO

April 2016. Bruno Jactel, CEO Erica Boisvert, CFO April 2016 Bruno Jactel, CEO Erica Boisvert, CFO OUR MISSION TYRATECH Is a life science technology company focused on: pesticide-free products to control insects and parasites 1 ton of pesticide per person/year!

More information

2008 Interim Results September 2008

2008 Interim Results September 2008 2008 Interim Results September 2008 Kenneth Alexander Chief Executive Gerard Cassels Finance Director Disclaimer This presentation is being made only in the United Kingdom and is directed only at (i) persons

More information

The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry

The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry Talentmark Consulting Product Driven People Solutions Press Release The Sage Group and Talentmark Consulting Announce Strategic Alliance for Services to the Global Healthcare & Life Sciences Industry Cambridge

More information

Annual Financial Results Presentation for year ended 30 June 2014 2 October 2014

Annual Financial Results Presentation for year ended 30 June 2014 2 October 2014 Annual Financial Results Presentation for year ended 30 June 2014 2 October 2014 Disclaimer The information contained in this presentation ( Presentation ) has been prepared by Firestone Diamonds plc (the

More information

Marel has agreed to acquire MPS meat processing systems for 382 million on a debt and cash-free basis Parallel Marel secured close to 670 million

Marel has agreed to acquire MPS meat processing systems for 382 million on a debt and cash-free basis Parallel Marel secured close to 670 million Marel has agreed to acquire MPS meat processing systems for 382 million on a debt and cash-free basis Parallel Marel secured close to 670 million senior long term financing for the group at favorable terms

More information

ONLINE TRAFFIC MONITIZATION EXPERT. 8 February

ONLINE TRAFFIC MONITIZATION EXPERT. 8 February ONLINE TRAFFIC MONITIZATION EXPERT 8 February 2015 1 About Us Who we are? We are an online performance marketing company What we do? We attract paying users from multiple online channels and direct them

More information

Monetising Online and Mobile Traffic. 26 March 2015

Monetising Online and Mobile Traffic. 26 March 2015 Monetising Online and Mobile Traffic 1 Disclaimer THIS PRESENTATION (THE PRESENTATION ) WHICH HAS BEEN PREPARED BY XLMEDIA PLC. (THE COMPANY) IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN

More information

EVT Execute & EVT Innovate Leading drug discovery

EVT Execute & EVT Innovate Leading drug discovery EVT Execute & EVT Innovate Leading drug discovery Evotec AG, Nine-month 2015 Interim Report, 10 November 2015 Forward-looking statements Information set forth in this presentation contains forward-looking

More information

Abbott Diagnostics. Durable Growth Business

Abbott Diagnostics. Durable Growth Business Abbott Diagnostics Durable Growth Business Forward-Looking Statement Some statements in this presentation may be forward-looking statements for purposes of the Private Securities Litigation Reform Act

More information

Innovative genetics research and biomarker solutions to advance molecular medicine. Corporate Overview

Innovative genetics research and biomarker solutions to advance molecular medicine. Corporate Overview Innovative genetics research and biomarker solutions to advance molecular medicine Corporate Overview April 2013 1 Oxford Gene Technology (OGT) Advancing molecular medicine Well-established private genomics

More information

Introduction to Entertainment One. Investor overview

Introduction to Entertainment One. Investor overview Introduction to Entertainment One Investor overview eone is a leading global entertainment company Group overview Entertainment One Ltd. is listed in London, a constituent of the FTSE 250 Index capitalised

More information

UDG Healthcare plc An International Healthcare Services Organisation

UDG Healthcare plc An International Healthcare Services Organisation UDG Healthcare plc An International Healthcare Services Organisation Jefferies 2014 Global Healthcare Conference 2014 Liam FitzGerald, CEO 20 November 2014 1 FORWARD LOOKING STATEMENTS Some statements

More information

OraSure Technologies, Inc. Jefferies 2015 Global Healthcare Conference

OraSure Technologies, Inc. Jefferies 2015 Global Healthcare Conference OraSure Technologies, Inc. Jefferies 2015 Global Healthcare Conference Forward-Looking Statements These slides and the associated presentation contain certain forward-looking statements, including statements

More information

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION INTO OR IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN. 6 June 2007

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION INTO OR IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN. 6 June 2007 NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION INTO OR IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN 6 June 2007 Amsterdam Molecular Therapeutics announces launch of Initial Public Offering (IPO) on Euronext

More information

Company presentation. Acquisition of Asan (Cederroth AS) and contemplated private placement. 17 December 2015

Company presentation. Acquisition of Asan (Cederroth AS) and contemplated private placement. 17 December 2015 Company presentation Acquisition of Asan (Cederroth AS) and contemplated private placement 17 December 2015 1 Disclaimer This presentation (the "Presentation") has been produced by Weifa ASA (the Company

More information

Market Update and Capital Raising 12 November, 2008

Market Update and Capital Raising 12 November, 2008 Market Update and Capital Raising 12 November, 2008 Dr Colin Goldschmidt CEO and Managing Director Sonic Healthcare 1 NOT FOR DISTRIBUTION IN THE UNITED STATES OR TO US PERSONS Important Notice and Disclaimer

More information

EUROPE S LEADING ONLINE FASHION DESTINATION Q4 / Full-Year 2014 Earnings Call 5 March 2015

EUROPE S LEADING ONLINE FASHION DESTINATION Q4 / Full-Year 2014 Earnings Call 5 March 2015 EUROPE S LEADING ONLINE FASHION DESTINATION Q4 / Full-Year 2014 Earnings Call 5 March 2015 Results highlights and business update 1 CONTINUED CLEAR FOCUS ON EXECUTION Strong revenue growth outperforms

More information

OW BUNKER ANNOUNCES INTENTION TO LAUNCH AN IPO AND TO SEEK A LISTING ON NASDAQ OMX COPENHAGEN

OW BUNKER ANNOUNCES INTENTION TO LAUNCH AN IPO AND TO SEEK A LISTING ON NASDAQ OMX COPENHAGEN PRESS RELEASE 5 March 2014 NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN This announcement is not a prospectus

More information

Alternative Networks plc Interim results for the six months to 31 March 2015

Alternative Networks plc Interim results for the six months to 31 March 2015 Alternative Networks plc Interim results for the six months to 31 March 2015 Edward Spurrier, Chief Executive Officer Mark Quartermaine, Chief Operating Officer (CEO Designate) Gavin Griggs, Chief Financial

More information

Cautionary Statement

Cautionary Statement Cautionary Statement The following document contains certain forward-looking statements and forward-looking information, which is based on current expectations, estimates, projections, assumptions and

More information

OPKO Health to Acquire Bio-Reference Laboratories

OPKO Health to Acquire Bio-Reference Laboratories OPKO Health to Acquire Bio-Reference Laboratories - Complementary in-depth expertise in diagnostics business with state of the art experience in use of genomic data for personalized therapy - Acquisition

More information

2015 Half-Year Results

2015 Half-Year Results 2015 Half-Year Results 26 August 2015 Copyright Copyright 2015 2015 APR Energy. APR Energy. All Rights All Rights Reserved. Reserved. APR Energy, APR Energy, its logo, its logo, and Powering and Powering

More information

Tungsten Corporation plc Results for the six months ending 31 October 2014

Tungsten Corporation plc Results for the six months ending 31 October 2014 Tungsten Corporation plc Results for the six months ending 31 October 2014 January 2015 Important information This document contains forward-looking statements that may or may not prove accurate. For example,

More information

2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q

2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q 2014 Wells Fargo Healthcare Conference June 17, 2014 NYSE: Q Copyright 2013 Quintiles Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements

More information

Pharming Group NV (Euronext: PHARM)

Pharming Group NV (Euronext: PHARM) Pharming Group NV (Euronext: PHARM) Sijmen de Vries, MD, MBA Chief Executive Officer Annual General Meeting of Shareholders Leiden, 30 April 2015 1 Safe harbour statement The information contained in this

More information

Craig Hallum Conference Investor Presentation

Craig Hallum Conference Investor Presentation Craig Hallum Conference Investor Presentation Improving cancer outcomes with groundbreaking precision in molecular testing Paul Kinnon President and CEO Sept 2015 1 Forward-Looking Statements Certain statements

More information

A leading developer of placenta-based cell therapy products October 1, 2014

A leading developer of placenta-based cell therapy products October 1, 2014 Pluristem Therapeutics, Inc. Initiating Report A leading developer of placenta-based cell therapy products October 1, 2014 Key data Sector Rating Biotechnology BUY Target Price $21.00 Current Market Price

More information

Industry Insight - Indian Biopharma

Industry Insight - Indian Biopharma Brochure More information from http://www.researchandmarkets.com/reports/2043221/ Industry Insight - Indian Biopharma Description: Biopharmaceuticals are complex macromolecules (Large molecules) created

More information

TERM SHEET EXAMPLE. 1 P age

TERM SHEET EXAMPLE. 1 P age 1 P age TERM SHEET EXAMPLE BIOTECHCO Overview & Business Strategy BIOTECHCO (the licensor), located in North Dakota, has a proprietary technology called ZIP that can generate fully human antibodies with

More information

J.P. Morgan Healthcare Conference 2014

J.P. Morgan Healthcare Conference 2014 January 13-16, 2014 J.P. Morgan Healthcare Conference 2014 Tecan Group AG Dr. David Martyr, CEO Safe Harbor Statement All statements in this presentation not referring to historical facts are predictions

More information

Update following the publication of the Bank of England Stress Test. 16 December 2014

Update following the publication of the Bank of England Stress Test. 16 December 2014 Update following the publication of the Bank of England Stress Test 16 December 2014 Background Top 8 Banks Resilience Stress Tested by PRA following FPC recommendation in March 2013 Guidance for stress

More information

Raymond James 37 th Annual Institutional Investors Conference March 8, 2016

Raymond James 37 th Annual Institutional Investors Conference March 8, 2016 Raymond James 37 th Annual Institutional Investors Conference March 8, 2016 Brian McKeon, Executive Vice President and Chief Financial Officer Safe Harbor Disclaimer The following information contains

More information

ZOO Digital Group plc AGM Presentation September 2013. Stuart Green, CEO

ZOO Digital Group plc AGM Presentation September 2013. Stuart Green, CEO ZOO Digital Group plc AGM Presentation September 2013 Stuart Green, CEO This document has been prepared by ZOO Digital Group plc (the Company ) solely for presentation purposes. It should not be reproduced,

More information

Saft Groupe SA Full year results 2014

Saft Groupe SA Full year results 2014 Saft Groupe SA Full year results 2014 Paris, February 18 th, 2015 Disclaimer This document contains certain forward-looking statements relating to the business, financial performance and results of the

More information

Sberbank Group s IFRS Results for 6 Months 2013. August 2013

Sberbank Group s IFRS Results for 6 Months 2013. August 2013 Sberbank Group s IFRS Results for 6 Months 2013 August 2013 Summary of 6 Months 2013 performance: Income Statement Net profit reached RUB 174.5 bn (or RUB 7.95 per ordinary share), a 0.5% decrease on RUB

More information

London Stock Exchange Symbol: PLUS

London Stock Exchange Symbol: PLUS London Stock Exchange Symbol: PLUS 1 Disclaimer The Presentation does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe

More information

Public funding policies: which options for small innovative companies in 2009. Biotech SMEs in the EU: how to improve access to finance

Public funding policies: which options for small innovative companies in 2009. Biotech SMEs in the EU: how to improve access to finance Public funding policies: which options for small innovative companies in 2009 Biotech SMEs in the EU: how to improve access to finance Dirk Carrez Director, EuropaBio EuroBio - 25 September 2009 (Lille)

More information

Recommended Acquisition of Networkers International plc Presentation to Analysts & Investors

Recommended Acquisition of Networkers International plc Presentation to Analysts & Investors Recommended Acquisition of Networkers International plc Presentation to Analysts & Investors 28 January 2015 Disclaimer THIS PRESENTATION IS NOT AN OFFER OR SOLICITATION OF AN OFFER TO BUY OR SELL SECURITIES.

More information

The Board reviews risks to the Company s business plan at its scheduled meetings.

The Board reviews risks to the Company s business plan at its scheduled meetings. Pharmaxis Ltd 1. Board responsibility The Pharmaxis Board is responsible for ensuring the Company establishes and maintains a risk management framework for the oversight and management of risk. The Board

More information

Key Findings. Use this report to... The Top 10 Contract Research Organizations

Key Findings. Use this report to... The Top 10 Contract Research Organizations Key Findings The global CRO industry valued $18bn in 2008, an increase of 14% over 2007. The CRO market will grow at an annual rate of 14% over the 2009 13 period. Quintiles leads the global CRO market

More information

Organic Growth and Strategic Acquisitions. Delivered record 66 million of validated cost savings to our customers

Organic Growth and Strategic Acquisitions. Delivered record 66 million of validated cost savings to our customers 2014 Preliminary Results For the year ended 31 December 2014 Organic Growth and Strategic Acquisitions Delivered record 66 million of validated cost savings to our customers Agenda Overview Financial highlights

More information

Collagen Solutions plc

Collagen Solutions plc Collagen Solutions plc Dr Stewart White Chief Executive Officer Exhibition Booth 24 Disclaimer This presentation is incomplete without reference to, and should be viewed solely in conjunction with the

More information

PROMETIC LIFE SCIENCES INC.

PROMETIC LIFE SCIENCES INC. PROMETIC LIFE SCIENCES INC. Investor Update July to September 2002 This present release must be considered as the quarterly report to shareholders. 1. Letter to Shareholders Dated November 21, 2002 2.

More information

RUNNINGBALL ACQUISITION INVESTOR PRESENTATION

RUNNINGBALL ACQUISITION INVESTOR PRESENTATION RUNNINGBALL ACQUISITION INVESTOR PRESENTATION TRANSACTION HIGHLIGHTS Proposed acquisition of RunningBall group, a leading provider of real-time sports data to the online sports betting sector Consideration

More information

Gjensidige Insurance Group Q4 2008 and preliminary 2008

Gjensidige Insurance Group Q4 2008 and preliminary 2008 Gjensidige Insurance Group Q4 2008 and preliminary 2008 Disclaimer The information contained herein has been prepared by and is the sole responsibility of Gjensidige Forsikring BA ( the Company ). Such

More information

Reed Elsevier Results 2013 Erik Engstrom, CEO Duncan Palmer, CFO

Reed Elsevier Results 2013 Erik Engstrom, CEO Duncan Palmer, CFO Reed Elsevier Results Erik Engstrom, CEO Duncan Palmer, CFO FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of Section 27A of the US Securities Act of

More information

Q1 Results 2014. Geoffrey McDonough CEO Alan Raffensperger COO Mats-Olof Wallin CFO. Stockholm 8 May 2014

Q1 Results 2014. Geoffrey McDonough CEO Alan Raffensperger COO Mats-Olof Wallin CFO. Stockholm 8 May 2014 Q1 Results 2014 Geoffrey McDonough CEO Alan Raffensperger COO Mats-Olof Wallin CFO Stockholm 8 May 2014 Highlights Q1 2014 Business Q1 US FDA approved Alprolix Kiobrina pivotal phase 3 study did not meet

More information

A Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations

A Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations A Cost Effective Way to De Risk Biomarker Clinical Trials: Early Development Considerations Ce3, Inc. and Insight Genetics, Inc. Oncology Forum July 15, 2015 Agenda Introductions Definitions Regulations

More information

Next Generation Sequencing Informatics Markets

Next Generation Sequencing Informatics Markets Next Generation Sequencing Informatics Markets Greg Caressi SVP Healthcare & Life Sciences November, 2014 Personalization, Communication, Decentralization, Collaboration From... One Size Fits All APPROACH...To

More information

Standard #2 If you right click on a Agenda slide in the left navigation bar you can choose between other slide layouts. TIP:

Standard #2 If you right click on a Agenda slide in the left navigation bar you can choose between other slide layouts. TIP: Annual Report 2014 Agenda 2 Full year results FY 2014 Exiqon Life Sciences Exiqon Diagnostics Corporate objective and investment case Financial calendar and outlook for 2015 Full year results 2014 - Q4

More information

Smart Metering Systems plc. Interim Results For the half year ended 30 June 2015

Smart Metering Systems plc. Interim Results For the half year ended 30 June 2015 Smart Metering Systems plc Interim Results For the half year ended 2015 Introduction and agenda Business review Alan Foy, CEO SMS story Financial Operational Financial review Glen Murray, CFO Highlights

More information

SAP Debt Investor Presentation First Quarter 2014 Update Call Walldorf, Germany April 28, 2014

SAP Debt Investor Presentation First Quarter 2014 Update Call Walldorf, Germany April 28, 2014 SAP Debt Investor Presentation First Quarter 2014 Update Call Walldorf, Germany April 28, 2014 Safe Harbor Statement Any statements contained in this document that are not historical facts are forward-looking

More information

Investor & Analyst Presentation Acquisition of Centor US Holding Inc. Uwe Röhrhoff, CEO Rainer Beaujean, CFO Duesseldorf, July 28, 2015

Investor & Analyst Presentation Acquisition of Centor US Holding Inc. Uwe Röhrhoff, CEO Rainer Beaujean, CFO Duesseldorf, July 28, 2015 Investor & Analyst Presentation Acquisition of Centor US Holding Inc. Uwe Röhrhoff, CEO Rainer Beaujean, CFO Duesseldorf, July 28, 2015 Disclaimer 1. This presentation may contain certain forward-looking

More information

Geoff Miller CEO. GLI Finance. February 2014

Geoff Miller CEO. GLI Finance. February 2014 Geoff Miller CEO GLI Finance February 2014 1 Disclaimer IMPORTANT NOTICE These presentation materials (the "Presentation Materials") are being solely issued to and directed at persons who are qualified

More information

H1/2014 Results VTG AG Growing together. Dr. Heiko Fischer, CEO Dr. Kai Kleeberg, CFO August 21, 2014

H1/2014 Results VTG AG Growing together. Dr. Heiko Fischer, CEO Dr. Kai Kleeberg, CFO August 21, 2014 H1/2014 Results VTG AG Growing together Dr. Heiko Fischer, CEO Dr. Kai Kleeberg, CFO August 21, 2014 Table of content 1 Discussion of H1/2014 2 Outlook FY 2014 3 Questions & Answers 4 Financial Calendar

More information

Emerging market opportunities for Roche. Luke Miels, Head of Asia-Pacific Roche Pharmaceuticals

Emerging market opportunities for Roche. Luke Miels, Head of Asia-Pacific Roche Pharmaceuticals Emerging market opportunities for Roche Luke Miels, Head of Asia-Pacific Roche Pharmaceuticals International region overview Eastern Europe & Middle East Asia Pacific Africa Latin America Market drivers

More information

DiaGenic ASA Grenseveien 92, N-0663 Oslo, Norway Tel +47 23 24 89 50 Mail: diagenic@diagenic.com DiaGenic ASA www.diagenic.com Slide #1 DiaGenic.

DiaGenic ASA Grenseveien 92, N-0663 Oslo, Norway Tel +47 23 24 89 50 Mail: diagenic@diagenic.com DiaGenic ASA www.diagenic.com Slide #1 DiaGenic. DiaGenic ASA Grenseveien 92, N-0663 Oslo, Norway Tel +47 23 24 89 50 Mail: diagenic@diagenic.com www.diagenic.com DiaGenic ASA Slide #1 UK Press Coverage Slide #2 Markets: Large, fast growing. Unmet medical

More information

Investor Presentation 2010 Financial Results Full Year ended 30 June. Rebecca Norton, Chief Financial Officer

Investor Presentation 2010 Financial Results Full Year ended 30 June. Rebecca Norton, Chief Financial Officer Investor Presentation 2010 Financial Results Full Year ended 30 June Simon Full Year Woodfull, results Group CEO for year ended Rebecca Norton, Chief Financial Officer August 2010 AGENDA Group Highlights

More information

EUROPE S LEADING ONLINE FASHION DESTINATION Q3 2015 Earnings Call 12 November 2015

EUROPE S LEADING ONLINE FASHION DESTINATION Q3 2015 Earnings Call 12 November 2015 EUROPE S LEADING ONLINE FASHION DESTINATION Q3 2015 Earnings Call 12 November 2015 Results highlights and business update 1 ACCELERATING GROWTH THROUGH TARGETED INVESTMENTS Strong Growth revenue accelerates

More information

Acquisition of SAIT Communications. 28 July 2015

Acquisition of SAIT Communications. 28 July 2015 Acquisition of SAIT Communications 28 July 2015 Conference call details SpeedCast acquires SAIT Communications The company has scheduled a conference call as follows: Time: 11.00am (Sydney time), 28 th

More information

Dr Alexander Henzing

Dr Alexander Henzing Horizon 2020 Health, Demographic Change & Wellbeing EU funding, research and collaboration opportunities for 2016/17 Innovate UK funding opportunities in omics, bridging health and life sciences Dr Alexander

More information

Second Quarter and First Half 2015 Trading Update

Second Quarter and First Half 2015 Trading Update Second Quarter and First Half 2015 Trading Update Trading Performance Year-on-Year Gross Profit Reported ( m) Constant 2015 2014 % % Q2 145.3 137.1 +6.0% +10.6% H1 281.0 263.7 +6.6% +10.8% Q2 Gross Profit

More information

QSC AG. Company Presentation. Preliminary Results 2013 / Outlook for 2014 Cologne, February 26, 2014

QSC AG. Company Presentation. Preliminary Results 2013 / Outlook for 2014 Cologne, February 26, 2014 QSC AG Company Presentation Preliminary Results 2013 / Outlook for 2014 Cologne, February 26, 2014 AGENDA 1. Strategic Development 2013 2. Financial Development 2013 3. Outlook for 2014 4. Questions &

More information

EUROPE S LEADING ONLINE FASHION DESTINATION Capital Markets Day: Advertising Services 25 March 2015

EUROPE S LEADING ONLINE FASHION DESTINATION Capital Markets Day: Advertising Services 25 March 2015 EUROPE S LEADING ONLINE FASHION DESTINATION Capital Markets Day: Advertising Services 25 March 2015 ADVERTISING SERVICES CREATES A WIN-WIN-WIN SITUATION FOR CUSTOMERS, BRANDS/ADVERTISERS AND ZALANDO CUSTOMERS

More information

BUY Target: 215p. Strategic impact: cross-selling. Financial impact: good value

BUY Target: 215p. Strategic impact: cross-selling. Financial impact: good value UK Daily Letter 1 K3 Business Technology Group KBT : AIM : 144p BUY Target: 215p Bob Liao, CFA 44.20.7050.6654 bliao@canaccordgenuity.com COMPANY STATISTICS: 52-week Range: 0.82-1.50 Avg. Daily Vol. (000s):

More information

AFFITECH and XOMA Sign Antibody Collaboration and Cross-License Agreement

AFFITECH and XOMA Sign Antibody Collaboration and Cross-License Agreement FOR IMMEDIATE RELEASE Ref 05AFF05 Contacts for Affitech: Contacts for XOMA Affitech (Norway): Investor Inquiries Dr. Martin Welschof Ellen M Martin Chief Executive Officer Kureczka/Martin Associates Phone:

More information

Hydrogenics Reports Fourth Quarter and Full Year 2015 Results

Hydrogenics Reports Fourth Quarter and Full Year 2015 Results PRESS RELEASE Hydrogenics Reports Fourth Quarter and Full Year 2015 Results Kolon, Alstom, and China Wins Highlight 2015 Achievements Mississauga, Ontario. March 9, 2016 Hydrogenics Corporation (NASDAQ:

More information

Annual General Meeting of Shareholders 19 May 2010

Annual General Meeting of Shareholders 19 May 2010 Annual General Meeting of Shareholders 19 May 2010 2009 results 2010 Q1 highlights Arnoud van Tulder CEO 19 May 2010 www.cryo-savegroup.com Highlights 2009 Strong financial results and cash position year

More information

Regulatory Issues in Genetic Testing and Targeted Drug Development

Regulatory Issues in Genetic Testing and Targeted Drug Development Regulatory Issues in Genetic Testing and Targeted Drug Development Janet Woodcock, M.D. Deputy Commissioner for Operations Food and Drug Administration October 12, 2006 Genetic and Genomic Tests are Types

More information

Clinical Trial Trends Outline Complexity for Supply Chain. Scott Ohanesian, VP Commercial Operations APAC Email: Scott.Ohanesian@marken.

Clinical Trial Trends Outline Complexity for Supply Chain. Scott Ohanesian, VP Commercial Operations APAC Email: Scott.Ohanesian@marken. Clinical Trial Trends Outline Complexity for Supply Chain Scott Ohanesian, VP Commercial Operations APAC Email: Scott.Ohanesian@marken.com 29 May 2013 Biotechnology Sales on the Rise Source: EvaluatePharma

More information

EUROPE S LEADING ONLINE FASHION DESTINATION Q3 Earnings Call 26 November 2014

EUROPE S LEADING ONLINE FASHION DESTINATION Q3 Earnings Call 26 November 2014 EUROPE S LEADING ONLINE FASHION DESTINATION Q3 Earnings Call 26 November 2014 Results highlights and business update 1 CLEAR FOCUS ON EXECUTION Continued strong revenue growth above market (Revenue in

More information

Investor Pack for 2014-15 Half Year Results. 20 February 2015

Investor Pack for 2014-15 Half Year Results. 20 February 2015 Investor Pack for 2014-15 Half Year Results 20 February 2015 1 Disclaimer This investor presentation ( Presentation ) has been prepared by Konekt Limited (ACN 009 155 971) ( KKT or Konekt ). SUMMARY INFORMATION

More information

Preliminary Results Presentation. For the year ended 30 th June 2013

Preliminary Results Presentation. For the year ended 30 th June 2013 Preliminary Results Presentation For the year ended 30 th June 2013 Contents Financial Highlights Operational Highlights Overview of Activities Product Group Segmental Analysis Operational Summary Financials

More information

Enhancing Value With Financial & Operational Excellence

Enhancing Value With Financial & Operational Excellence Enhancing Value With Financial & Operational Excellence Robert Hombach CFO & COO Enhancing Value With Financial & Operational Excellence Growing Sales & Earnings Generating value in attractive markets

More information

2015 FIRST HALF RESULTS CONFERENCE CALL. August 31st, 2015

2015 FIRST HALF RESULTS CONFERENCE CALL. August 31st, 2015 2015 FIRST HALF RESULTS CONFERENCE CALL August 31st, 2015 DISCLAIMER This presentation has been prepared by Eurotech S.p.A.(or Eurotech ) and has to be read in conjunction with its oral presentation. The

More information

The Cell Therapy Catapult

The Cell Therapy Catapult The Cell Therapy Catapult Keith Thompson CEO January 29 2013 info@ct.catapult.org.uk Catapult is a Technology Strategy Board programme The Launch of Catapults Hauser 2 Hauser Report Creating new manufacturing

More information

Defining Growth in the Rum Category. 3 December 2010

Defining Growth in the Rum Category. 3 December 2010 Defining Growth in the Rum Category 3 December 2010 Ed Pilkington Global Category Director, Vodka, Gin and Rum 2 Map of rum producing countries google maps. 3 Rum, colourful past - exciting future * Source:

More information

SAF-HOLLAND Annual Financial Statements 2012. Detlef Borghardt, CEO Wilfried Trepels, CFO. March 14, 2013

SAF-HOLLAND Annual Financial Statements 2012. Detlef Borghardt, CEO Wilfried Trepels, CFO. March 14, 2013 SAF-HOLLAND Annual Financial Statements 212 Detlef Borghardt, CEO Wilfried Trepels, CFO March 14, 213 Executive Summary business volume successfully expanded in 212 1 Group sales increased yoy by 3.4%

More information

World-leading expertise in Gene and Cell Therapy

World-leading expertise in Gene and Cell Therapy Worldleading expertise in Gene and Cell Therapy Jefferies Healthcare Conference New York, June 2015 Disclaimer The information contained in this presentation is being supplied and communicated to you on

More information

CLINICAL COMPUTING PLC 2009 PRELIMINARY RESULTS

CLINICAL COMPUTING PLC 2009 PRELIMINARY RESULTS CLINICAL COMPUTING PLC 2009 PRELIMINARY RESULTS Clinical Computing Plc (the Company or the Group ), the international developer of clinical information systems and project and resource management software,

More information

Unlock Your Global Business Potential: Supporting Life Sciences in the UK

Unlock Your Global Business Potential: Supporting Life Sciences in the UK Unlock Your Global Business Potential: Supporting Life Sciences in the UK Dr Mark Treherne, Chief Executive, Life Science Investment Organisation Health Research Authority 31 st March, 2014 THE UK HAS

More information

For personal use only CREATE, SUPPLY AND SUPPORT

For personal use only CREATE, SUPPLY AND SUPPORT INTRODUCTION Inabox is well advanced in transitioning its business from a legacy telecommunications wholesaler to become a leading supplier of next generation IT, cloud and IP telephony services Process

More information

KRONES Financial Year 2015 Preliminary Figures. Conference Call March 17, 2016

KRONES Financial Year 2015 Preliminary Figures. Conference Call March 17, 2016 KRONES Financial Year 2015 Preliminary Figures Conference Call March 17, 2016 2 KRONES Conference Call March 17, 2016 Highlights 2015 Financials 2015 Outlook 2016 3 KRONES Conference Call March 17, 2016

More information

J.P. Morgan 2016 Healthcare Conference CEO. January 12, 2016 NYSE: Q. Copyright 2016 Quintiles

J.P. Morgan 2016 Healthcare Conference CEO. January 12, 2016 NYSE: Q. Copyright 2016 Quintiles J.P. Morgan 2016 Healthcare Conference Tom Pike CEO January 12, 2016 Copyright 2016 Quintiles NYSE: Q Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking

More information

Biotechnology and Life Science Marketing Services Mailing List and Data Card Order Form

Biotechnology and Life Science Marketing Services Mailing List and Data Card Order Form C H I Cambridge Healthtech Institute s Biotechnology and Life Science Marketing Services Mailing List and Data Card Order Form Over 800,000 names segmented by scientific interest Featuring U.S and International

More information

Acquisition of Naked Wines International Ltd: A Transformational Deal 10 APRIL 2015

Acquisition of Naked Wines International Ltd: A Transformational Deal 10 APRIL 2015 Acquisition of Naked Wines International Ltd: A Transformational Deal 10 APRIL 2015 Phil Wrigley Chairman Transformational deal for Majestic Wine Plc ( Majestic ) The global wine market is an attractive

More information

Quarterly cash flow and activities report 30 June 2015

Quarterly cash flow and activities report 30 June 2015 Quarterly cash flow and activities report 30 June 2015 Genetic Signatures (ASX: GSS) is pleased to report on its activities for the quarter ended 30 June 2015. Highlights: Continued growth in sales of

More information

Building innovative drug discovery alliances. Profitable. Growth Go

Building innovative drug discovery alliances. Profitable. Growth Go Building innovative drug discovery alliances Innovation n & Profitable Growth Go Evotec AG, H1 Presentation, 8 th August 2012 Forward-looking statements Information set forth in this presentation contains

More information

McKesson Corporation J.P. Morgan Healthcare Conference

McKesson Corporation J.P. Morgan Healthcare Conference McKesson Corporation J.P. Morgan Healthcare Conference John Hammergren Chairman and Chief Executive Officer January 13, 2015 Forward-Looking Statements Some of the information in this presentation is not

More information

Company Presentation VTG AG Connecting worlds. Analyst Conference April 14, 2015

Company Presentation VTG AG Connecting worlds. Analyst Conference April 14, 2015 Company Presentation VTG AG Connecting worlds Analyst Conference April 14, 2015 Table of content 1 Highlights 2014 2 Performance & Financials 2014 3 Update on Strategy 4 Outlook 2015 5 Appendix 1 Executive

More information

Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset

Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset Introduction In this era of strategic development deals, inventiv Health has significantly broadened

More information

Adaptimmune Reports Full Fiscal Year 2015 Financial Results. - Conference call to be held today at 8:00 AM ET (1:00 PM BST) -

Adaptimmune Reports Full Fiscal Year 2015 Financial Results. - Conference call to be held today at 8:00 AM ET (1:00 PM BST) - Adaptimmune Reports Full Fiscal Year 2015 Financial Results - Conference call to be held today at 8:00 AM ET (1:00 PM BST) - PHILADELPHIA, Pa. and OXFORD, United Kingdom., October 13, 2015 Adaptimmune

More information

19 October 2006. Company Announcement Office Bendigo Stock Exchange PO Box 191 Flinders Lane, Melbourne Vic 8009. By email; announcements@bsx.com.

19 October 2006. Company Announcement Office Bendigo Stock Exchange PO Box 191 Flinders Lane, Melbourne Vic 8009. By email; announcements@bsx.com. 19 October 2006 Company Announcement Office Bendigo Stock Exchange PO Box 191 Flinders Lane, Melbourne Vic 8009 By email; announcements@bsx.com.au RE: Announcement by State Development Fund Limited Please

More information